Shopping Cart
- Remove All
- Your shopping cart is currently empty
PLK1-IN-9 (Compound M2), a polo-like kinase 1 (PLK1) inhibitor, targets the PLK proteins modified with peptides 1010pT, cdc25c, and PBIP, exhibiting IC50 values of 1.6, 0.8, and 1.4 μM, respectively. This compound effectively inhibits the proliferation of various cancer cell lines including HeLa, HL60, SNU387/499, and HepG2, demonstrating cytotoxic effects and inducing apoptosis. Additionally, PLK1-IN-9 has been shown to suppress tumor growth in a HepG2 xenograft mouse model.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | PLK1-IN-9 (Compound M2), a polo-like kinase 1 (PLK1) inhibitor, targets the PLK proteins modified with peptides 1010pT, cdc25c, and PBIP, exhibiting IC50 values of 1.6, 0.8, and 1.4 μM, respectively. This compound effectively inhibits the proliferation of various cancer cell lines including HeLa, HL60, SNU387/499, and HepG2, demonstrating cytotoxic effects and inducing apoptosis. Additionally, PLK1-IN-9 has been shown to suppress tumor growth in a HepG2 xenograft mouse model. |
Molecular Weight | 296.20 |
Formula | C12H7F3N4O2 |
Cas No. | 893772-67-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.